Secukinumab for rheumatology: development and its potential place in therapy - Wikidata - wikimedia - TriplyDB

Secukinumab for rheumatology: development and its potential place in therapy

Secukinumab for rheumatology: development and its potential place in therapy

http://www.wikidata.org/entity/Q26738523

about

Selected cytokine pathways in rheumatoid arthritis.A Review of the Use of Secukinumab for Psoriatic Arthritis.Functional and structural characterization of osteocytic MLO-Y4 cell proteins encoded by genes differentially expressed in response to mechanical signals in vitro.

P2860

Q38755912-2AD6AD33-9A38-4F81-B1AB-C5697A6AD8B1 Q47160133-8E2D99AB-ED87-4268-8BA8-127C846B7947 Q55311483-4886B411-8C6C-435B-99BB-EE90D10BEE53

P2860

Secukinumab for rheumatology: development and its potential place in therapy

http://www.wikidata.org/entity/Q26738523

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Secukinumab for rheumatology: development and its potential place in therapy

@ast

Secukinumab for rheumatology: development and its potential place in therapy

@en

Secukinumab for rheumatology: development and its potential place in therapy

@nl

type

label

Secukinumab for rheumatology: development and its potential place in therapy

@ast

Secukinumab for rheumatology: development and its potential place in therapy

@en

Secukinumab for rheumatology: development and its potential place in therapy

@nl

prefLabel

Secukinumab for rheumatology: development and its potential place in therapy

@ast

Secukinumab for rheumatology: development and its potential place in therapy

@en

Secukinumab for rheumatology: development and its potential place in therapy

@nl

P1433

Q26738523-56327E29-4112-4C55-B19F-D8526EAB2F77

P1476

Q26738523-E6A313DF-A991-47C5-AF18-4330B0A3AA2E

P2093

Q26738523-5CB0A66A-C39A-462A-8629-968109B9C05A

Q26738523-AF43F482-2243-4A5D-9CEB-C826357CAECC

P275

Q26738523-B0D2F3FD-2E79-424B-B287-FEFA0823A29D

P2860

Q26738523-0481D311-30AF-467A-B524-DCECF56002C0

Q26738523-06D3EF29-1E7E-4CFA-AB61-6CA02EC1633A

Q26738523-07F30B73-FDB9-46C3-A8DB-D63BFE07A51A

Q26738523-08D06335-1991-430C-8845-AC00BCA53080

Q26738523-0AD59638-6D18-436C-B084-6CFEDCF6BD74

Q26738523-16A1845D-78EE-4F94-B596-BF9CD38D6AB7

Q26738523-1AE34D63-5F38-4095-801A-A9C76E26DBF4

Q26738523-26EDEDED-E494-4FD0-B853-04B67A47B509

Q26738523-2AD22B48-23AD-40D8-9365-060E8B627A35

Q26738523-2E286DB7-45DD-4285-A325-BE8FFB34153E

P304

Q26738523-6316953A-96CD-4E15-8AAE-0A2D051B1635

P31

Q26738523-6A81CE58-FB01-4CB3-9267-40FC8562964D

Q26738523-8D9ECF4F-1C9F-4BF2-B91C-C905C6B51FA5

P3181

Q26738523-68E29AAA-D721-401A-AEB9-167266CA4828

P356

Q26738523-D2F0CB6B-B2B1-4DE6-AD8F-3CA8BAD57045

P407

Q26738523-811AD2EE-473C-4EEA-B606-5E1D32A0B6D6

P478

Q26738523-F0733D97-480D-4B6B-9BE2-C0AF7B55F520

P5008

Q26738523-9BD7FA19-8620-4A77-83A8-759C5A58AA75

P577

Q26738523-949FD034-2B97-446C-88FE-D244FA7FE532

P698

Q26738523-357014C7-EEA6-4B4F-BCBD-E545FA8495F7

P921

Q26738523-0BF13670-061E-4601-B7BA-87433D8C501F

Q26738523-12D57592-B96F-4407-AEB8-456ED81C2AEE

Q26738523-288B09FA-9D4D-46AC-983C-DC7F287C3EBC

Q26738523-39DA31EF-9EC1-46D9-80F2-5DEB371D5FB9

Q26738523-4B07C7D1-0AA5-44C9-BD93-63900E0AF066

Q26738523-87730310-E5E7-4385-BEC6-84FB6BF43CD2

Q26738523-D118B99C-EA3B-4848-8A53-CAD3526A7F85

Q26738523-F2D1000D-F9F5-46EE-A8D8-638C571D98EC

Q26738523-FF2C7FF3-D6C6-40ED-85ED-A4D7BFF08BE4

P932

Q26738523-D9145923-75D7-42E3-8058-951BAD915204

P3181

P356

P1433

Drug Design, Development and Therapy

P1476

Secukinumab for rheumatology: development and its potential place in therapy

@en

P2093

Marije I Koenders

http://www.w3.org/2001/XMLSchema#string

Wim B van den Berg

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthriti

CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

The biological functions of T helper 17 cell effector cytokines in inflammation

Structure and signalling in the IL-17 receptor family

The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat

Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction

T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

P304

2069-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

519055

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/DDDT.S105263

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27445458

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

Tumor necrosis factor

monoclonal antibody

psoriatic arthritis

ankylosing spondylitis

P932

4928657

http://www.w3.org/2001/XMLSchema#string